Skip to main content
. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789

Fig 2. Impact of BRCA1/2 P/LP variants on the DFS of subgroups with early stage.

Fig 2

Kaplan-Meier survival analysis; P values calculated using a log-rank analysis. Estimated DFS of breast cancer patients with stage 0~II by BRCA status: (A) BRCA1 and BRCA2 P/LP variants (germline or somatic); (B) Germline BRCA1 and BRCA2 P/LP variants. Estimated DFS of breast cancer patients with node negative disease by BRCA status: (C) BRCA1 and BRCA2 P/LP variants (germline or somatic); (D) Germline BRCA1 and BRCA2 P/LP variants.